Project

biotechnology netherlands

ENRICH-SARCOMA

Sarcomas are soft tissue tumors with limited treatment options, which often include radiation therapy. For some sarcomas, the benefit of radiation is limited, and enhancing its effect could improve patient outcomes.
Our research has focused on radiosensitization: increasing the sensitivity of tumors to radiation. We do this via administration of drugs that enrich tumor cells in more vulnerable stages of their cell cycles. We are currently developing MITX-101, a radiosensitizing drug which we will test in a clinical trial for glioblastoma in 2026.

The ENRICH-SARCOMA projectteam intends to study the potential for MITX-101 in preclinical sarcoma models in cell lines and mice, to identify several types of sarcoma for which this could be a promising therapeutic strategy. If this project demonstrates preclinical benefit, it is possible that MITX-101 could provide a low-burden add-on to improve treatment options for patients.
We already have a depth of experience working with MITX-101, and therefore a substantial supply of drug, and appropriate preparatory documentation to proceed to clinical use, making preclinical and clinical testing very efficient. In addition to the important data generated in this project on the potential for MITX-101 in sarcoma, we will also generate regulatory and development data and documents that will accelerate the progress to potentially helping sarcoma patients.

Project team

Olaf van Tellingen, PI / Mark de Gooijer, PI / Nadina Grosios, Regulatory Consultant / René Raggers, European Patent Attorney / Vincent Tissingh, Pharmacist / Rick Haas, Radiation Oncologist

Project Number

BIOB25011

Year granted

2025

Status

Ongoing

Applicant

Netherlands Cancer Institute

Funding

€ 200.000

Sector/Industry

Health & Pharma

SDG's

Good health and well-being (SDG 3)

Thematic Cluster

TC5: Vaccines, Small Molecules, Discovery & Development Platforms

Level

Level 1
Molecuul

2025

Year granted

Netherlands Cancer Institute

Applicant

€ 200.000

Project funded
Project story

Plant Beams: breaking through the plant barrier

The question that started Plant Beams For over ten years, David FernĂ¡ndez Rivas has worked on a technology that uses

Plant Beams: breaking through the plant barrier
Project story

SideroFORCE: Tricking bacteria to heal infection

We interviewed Wim Velema, projectleader of Biotech Booster project SideroFORCE, which joined our program in 2025. At sixteen, Wim liked

SideroFORCE: Tricking bacteria to heal infection
IBB

Behind the Bootcamp: Meet the IBB26 Coaches

Building an industrial biotech venture takes more than a great scientific idea. It requires the ability to challenge assumptions, make

Behind the Bootcamp: Meet the IBB26 Coaches
Project story

From Luggage Tags to Better Food

From fragmented DNA to better food on our plates. We interviewed Biotech Booster project Haplotagging to learn more about their

From Luggage Tags to Better Food
Impact developer portrait

The Innovation Journey at the Universities of Applied Sciences

Impact Developers help researchers turn their ideas into innovations that impact society. They connect researchers with companies and other partners

The Innovation Journey at the Universities of Applied Sciences
Alumni Column

Alumni column: Patrick Dekker from iProtics

On both sides of the table. Some people know Biotech Booster from the outside. Others experience it from the inside,

Alumni column: Patrick Dekker from iProtics
Citaat

Biotech Booster helps us through funding and by providing us with a network to validate where we can make the best impact with our new analysis device.

Biotechnology netherlands

Carlos de Lannoy

Constellate

Citaat

What we look forward to most is leveraging the extraordinary network of Biotech Booster that we need to get foot in the market, get know-how, and understanding the competitive field which is necessary for setting up successful operations.

Biotechnology netherlands

Pim Schaasberg & Martin Pabst

ProteoT

Moleculen

Newsletter

Receive monthly updates about our community!

Subscribe to our newsletter